ReNeuron Group plc Update for hRPC therapy candidate study (3482B)
June 09 2021 - 5:55AM
UK Regulatory
TIDMRENE
RNS Number : 3482B
ReNeuron Group plc
09 June 2021
ReNeuron Group plc
("ReNeuron" or the "Company")
Update for hRPC therapy candidate study
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, provides an update on the
Company's Phase 2a clinical evaluations for the treatment of
retinitis pigmentosa ('RP'), an inherited, degenerative eye
disease.
Further to the update on 15 January 2021, the Company has
activated sites in Spain and the UK, to expand the Phase 2a
extension study outside the US, thus representing a total of four
actively enrolling sites worldwide. The most recently enrolled
subject was treated last week, undergoing a successful surgical
procedure to implant the hRPC drug product. Five days following
treatment, the subject presented with a presumed bacterial
intraocular infection in the treated eye which impacted their
vision, and was treated initially with an appropriate regimen of
antibiotics, to which they responded with clinical improvement.
Systemic anti-inflammatory therapy was subsequently added, and the
subject continues to improve on this regimen.
The origin of the presumed infection is not yet clear. As a
precaution, dosing of further subjects in the study has been
temporarily suspended while an investigation into the cause of the
event continues. This is likely to lead to a delay to the study,
and the Company now expects three-month data from the extension
segment of the Phase 2a study to be available in Q4, rather than
Q3, of this year.
The Company will provide a further update in due course.
ENDS
Contacts:
ReNeuron www.reneuron.com/investors
Olav Hellebø, Chief Executive Via Walbrook PR
Officer
Stifel Nicolaus Europe Limited (NOMAD
and Joint Broker)
Ben Maddison, Stewart Wallace +44 (0)20 7710 7600
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate
Finance)
Tim Sohal (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407
Paul McManus, Alice Woodings 804 654
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments, without the need for immunosuppressive
drugs. The Company's lead cell therapy candidate is in clinical
development for the blindness-causing disease, retinitis
pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that treat
diseases of the brain. The Company also has the ability through its
conditionally immortalised induced pluripotent stem cell (iPSC)
platform to make any tissue cells of choice; in-house programmes
are focused on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDUPUGAQUPGGUB
(END) Dow Jones Newswires
June 09, 2021 06:55 ET (10:55 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2024 to Jun 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From Jun 2023 to Jun 2024